Latanoprost Plus Timolol Stada

Latanoprost, the active ingredient in Latanoprost Plus Timolol Stada, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It works together with timolol, a non‑selective beta‑blocker, to treat open‑angle glaucoma and ocular hypertension in adults by increasing aqueous outflow and reducing aqueous production.

GNH USA supplies Latanoprost Plus Timolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Plus Timolol is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family.

Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: reduces elevated eye pressure to lower risk of developing glaucoma. Pseudoexfoliative glaucoma: helps control pressure in this secondary form.

The ocular combination may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash growth - Eye irritation or foreign body sensation - Blurred vision - Dry eye - Mild ocular discomfort

Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis) - Significant bradycardia or heart block - Bronchospasm in patients with asthma or COPD - Marked deepening of the upper eyelid (ptosis) - Persistent corneal edema - Systemic hypotension

When prescribing Latanoprost Plus Timolol, clinicians should consider several safety measures.

Cardiovascular assessment: evaluate heart rate and blood pressure before initiating therapy. Respiratory status: avoid use in patients with asthma or severe chronic obstructive pulmonary disease. Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. Concurrent ocular medications: stagger administration to prevent washout effects. Systemic beta‑blocker use: monitor for additive bradycardic effects. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost Plus Timolol may interact with other medicines, requiring attention to avoid reduced efficacy or increased adverse effects.

Major Interactions (Avoid): - Other systemic beta‑blockers: may cause excessive bradycardia or hypotension. - Inhaled or oral sympathomimetics (e.g., epinephrine): may reduce ocular hypotensive effect. - Topical ocular anesthetics: can increase corneal toxicity when combined. - MAO inhibitors: potential for enhanced cardiovascular effects. - Non‑selective beta‑blocker eye drops: risk of additive systemic absorption.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may potentiate hypotensive response. - Anticholinergic eye drops: possible reduced efficacy of prostaglandin component. - Systemic antihypertensives: monitor blood pressure. - Other prostaglandin analogs: risk of additive ocular irritation. - Corticosteroid eye drops: may diminish intra‑ocular pressure lowering.